Edition:
United Kingdom

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

1.27USD
15 Jan 2019
Change (% chg)

-- (--)
Prev Close
$1.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,285
52-wk High
$5.36
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Cti Biopharma Announces 50 Pct Reduction In Workforce Expected
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA ANNOUNCES RESTRUCTURING PLAN.CTI BIOPHARMA CORP - FIFTY PERCENT REDUCTION IN WORKFORCE EXPECTED.CTI BIOPHARMA ANNOUNCES RESTRUCTURING PLAN.CTI BIOPHARMA CORP - COST SAVINGS OF APPROXIMATELY $20 MILLION PRIMARILY ASSOCIATED WITH REDUCED EMPLOYEE COSTS ARE EXPECTED OVER THREE YEARS.CTI BIOPHARMA - PLANS TO GIVE FINANCIAL GUIDANCE IN H12019 WHEN DETAILS OF U.S. PHASE 3 TRIAL DESIGN, INCLUDING TRIAL SIZE & DOSING SCHEDULE ARE KNOWN.  Full Article

CTI Biopharma May Offer, Sell Shares Of its Common Stock
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP SAYS CO MAY OFFER, SELL SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING.  Full Article

CTI Biopharma Reports Q3 Loss Per Share $0.26
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.26.PAC203 STUDY IS EXPECTED TO COMPLETE ENROLLMENT BY END OF 2018.TOP-LINE DATA FROM PAC203 STUDY EXPECTED IN Q2 OF 2019.FOLLOWING IDENTIFICATION OF OPTIMAL DOSE FROM PAC203 STUDY, CO EXPECTS TO BEGIN PHASE 3 PATIENT RECRUITMENT MID-YEAR IN 2019.AS OF SEPT 30, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $80.9 MILLION VERSUS $43.2 MILLION AS OF DEC 31, 2017.  Full Article

Cti Biopharma Q2 Loss Per Share $0.20
Thursday, 2 Aug 2018 

CTI Biopharma Corp ::CTI BIOPHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.20.  Full Article

CTI Biopharma Says Phase III Trial Evaluating Pixuvri With Rituximab In Comparison To Gemcitabine Combined With Rituximab Did Not Meet Its Primary Endpoint
Monday, 9 Jul 2018 

July 9 (Reuters) - CTI Biopharma Corp ::RESULTS OF PHASE III (PIX306) TRIAL EVALUATING PROGRESSION-FREE SURVIVAL OF PIXUVRI® (PIXANTRONE) COMBINED WITH RITUXIMAB IN PATIENTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA.CTI BIOPHARMA - PIXUVRI® PLUS RITUXIMAB DID NOT SHOW STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VERSUS GEMCITABINE PLUS RITUXIMAB.CTI BIOPHARMA - PHASE III TRIAL EVALUATING PIXUVRI WITH RITUXIMAB IN COMPARISON TO GEMCITABINE COMBINED WITH RITUXIMAB DID NOT MEET ITS PRIMARY ENDPOINT.CTI BIOPHARMA CORP - WILL PROCEED TO CONDUCT A THOROUGH REVIEW OF CLINICAL DATA TO ASSESS NEXT STEPS FOR PIXUVRI PROGRAM.  Full Article

CTI BioPharma to receive $10 mln milestone payment for Trisenox
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA TO RECEIVE $10 MILLION MILESTONE PAYMENT FOR TRISENOX®.CTI BIOPHARMA - ‍TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM TEVA PHARMACEUTICAL INDUSTRIES RELATED TO U.S. FDA APPROVAL OF TRISENOX​.  Full Article

CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​.CTI BIOPHARMA CORP - ‍PURSUANT TO AGREEMENT, LENDER HAS AGREED TO MAKE A SENIOR SECURED TERM LOAN OF UP TO $18 MILLION​.CTI BIOPHARMA CORP - ‍FIRST $16 MILLION OF TERM LOAN WAS FUNDED ON NOVEMBER 28, 2017​.  Full Article

CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​.  Full Article

CTI Biopharma reports third quarter 2017 financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - CTI Biopharma Corp ::CTI Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.28.CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million.  Full Article